News Hub | News Direct


Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test

Mainz Biomed N.V.

Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer screening product. This product incorporates a novel portfolio of mRNA biomarkers. Achieving this designation could potentially expedite the approval process, significantly benefiting early cancer detection efforts. Baechler emphasized that the regulatory submission is backed by consistently strong results from the company's clinical studies, ColoFuture and eAArly Detect, as well as data from a comprehensive pooled study encompassing both the European and U.S. cohorts, which were presented at ASCO 2024. These studies have culminated in the final configuration of the Next Generation Test. This test integrates the Fecal Immunochemical Test with proprietary mRNA biomarkers and is enhanced by an advanced AI and machine learning algorithm. This integrated approach is set to be employed in the FDA premarket approval study. The Next Generation Test configuration was rigorously evaluated in a clinical setting involving 295 subjects from 21 specialized gastroenterology centers across the United States. The results underscored the exceptional efficacy of Mainz Biomed’s multimodal screening test, which allows for precise differentiation among colorectal cancer, advanced adenomas, non-advanced adenomas, and samples with no pathological findings. The FDA’s Breakthrough Devices Designation program is designed to accelerate the development, assessment, and review of medical devices and combination products that provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. This designation for Mainz BioMed's colorectal cancer test could pave the way for quicker market access and wider availability of this critical diagnostic tool. Contact Details Proactive North America +1 604-688-8158

July 19, 2024 12:38 PM Eastern Daylight Time

Article thumbnail News Release

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma

After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will integrate AI-driven solutions to address the significant challenge of depression among cancer patients, a condition that often complicates treatment and adversely affects overall quality of life. Dr. Uttam Patil shared with Steve Darling from Proactive that the study aims to gain a deeper understanding of the prevalence and impact of depression in cancer patients. It will explore innovative therapeutic approaches by integrating real-time patient monitoring and enhanced patient analysis through an AI model. This advanced methodology is expected to increase the lead time for clinical trials, utilizing novel and sophisticated treatment protocols. The clinical study will be conducted at the renowned Cedars-Sinai Medical Center, involving cancer patients who experience depressive symptoms. By leveraging advanced AI technologies and employing cutting-edge diagnostic and therapeutic techniques, the study aims to monitor and treat depression in participants under meticulous medical supervision. Dr. Patil emphasized that the integration of AI-driven solutions in this clinical study represents a significant leap forward in the treatment of depression in cancer patients. The use of real-time patient monitoring and AI-based analysis is anticipated to provide valuable insights and improve patient outcomes, setting a new standard for clinical trials in this area. The collaboration between ABVC BioPharma and AiBtl BioPharma highlights their commitment to advancing healthcare through innovative solutions. This study is poised to make a substantial impact on the management of depression in cancer patients, offering hope for improved quality of life and better treatment outcomes. Through this pioneering study, ABVC BioPharma and AiBtl BioPharma are at the forefront of integrating technology with healthcare, paving the way for future advancements in the field. The companies are dedicated to utilizing AI to enhance patient care and accelerate the development of effective treatments for depression in cancer patients. Contact Details Proactive North America +1 604-688-8158

July 18, 2024 10:31 AM Eastern Daylight Time

Article thumbnail News Release

Freelance jobs grow despite AI, finds new data from

FREELANCER.COM (ASX: FLN), the world’s largest freelancing and crowdsourcing marketplace by number of users and jobs posted, today released its quarterly Fast 50 Index for Q2 2024 based on data from 251,000 jobs posted to the platform. Computer Security (up 27.1% from 868 to 1,103 jobs) emerges as the fastest-growing freelance skill on, based on job postings across more than 2,000 skill categories from April 1 to June 30, 2024. This trend in cybersecurity skills suggests more small-to-medium businesses are turning to freelancers for cyber security support, further backed by Network Administration (up 9.9%, from 1,229 to 1,351) also placing in the top 25 fastest growing jobs on the platform. The data also shows no negative impact on generative AI tools on freelance jobs, evident in the growth of Writing, Business Service, and Legal Skills seen in this quarter’s Fast 50 report, all of which were predicted to decrease with the rise in generative AI. PDF writing (up 26.7%, from 2,533 to 3,210) was the second fastest growing job, followed by third place being Microsoft Word (up 23.9%, from 3,368 to 4,173) projects which are also associated with content writing. Writing job Copy Typing came in at the 16th place, growing 11.6% (from 4,428 to 4,941). Legal jobs, which were expected to have been ‘at threat’ to AI, have also increased (up 12.0% from 1,138 to 1,274), as well as Legal Research (up 10.8% from 917 to 1,016). In addition to the index, ’s annual AI survey, which surveyed more than 4,100 workers globally, investigated AI impact on income and the initial results are shedding light on earnings. When asked how the introduction of AI tools have impacted earnings, more than half of workers (52.5%) reveal they’re earning either the same or more. One fifth (19.2%) say that they’re earning a lot more since generative AI tools were introduced, while only one sixth (17.7%) admit to earning less. “AI is creating more jobs than it takes. While many critics continue to speculate which jobs will be made redundant with AI tools, the data shows that freelance jobs which are labeled as the ‘most at risk to AI disruption’ are in fact growing. The preliminary results from our AI survey also dispel the myth that freelancer are earning less since the introduction of generative AI as more three quarters of workers we surveyed are either earning the same or earning more, with a subset taking advantage of AI and earning a lot more.” said Matt Barrie, Chief Executive at Cybersecurity threats are on the rise across all organizations, but are particularly harmful for small-to-medium sized businesses (SMBs) which have little-to-no security expertise and usually minimal protection. As a result, businesses turned to freelancers for help. In 2Q24, Computer Security jobs ranked as the fastest growing skills (up 27%), indicating there has been an uptick in cyber security threats targeting SMBs. Many of the projects posted throughout the quarter require help with network security, security assessments to identify potential vulnerabilities, and creation of cyber security response play books. General business services are also increasing on the platform as more employers are hiring freelancers to support their small businesses. A clear indication of this is the popularity of Market Research and Telemarketing jobs coming in as the fourth and fifth fastest growing skills in Q2 2024, up by 21.1% (from 1,525 to 1,859) and 19.4% (from 1,177 to 1,405), respectively. Other business related skills grew in Q2 2024, including Sales (up 15.5% from 3.467 to 4,005), Lead Generation (up 12.2% from 1,802 to 2,021) and Business Plans (up 10.9% from 1,197 to 1,328). A sudden increase in General business services means that many of the new businesses, which are usually started at the beginning of the year, now require further assistance in helping grow and scale their business. Fastest Falling Skills for Q2 2024 The main category of jobs that fell in Q2 2024 was eCommerce related jobs, which saw a significant increase in Q1 2024. Shopify Templates, ranked as the fastest falling skill and was down by 13% (from 1,476 to 1,284). CSS, which is commonly used in website development, was also down (11.8% from 9.486 to 8,368). Both WooCommerce (from 1.072 to 952) and Shopify (2,545 to 2,269) also fell in the quarter. The easing of eCommerce jobs in this quarter was mainly due to seasonality. Typically, entrepreneurs will start a business at the beginning of the year, requiring help to set up their websites or eCommerce platforms. From there, the entrepreneur either pivots to hiring freelancers for other business services, such as sales or research which we’ve seen in Q2 2024 fastest growing jobs, or are equipped with enough to run their business without any further help. Fastest Growing Overall Job The most popular online freelancing job by total volume is currently Graphic Design with almost double the amount of projects than the other top skills. Graphic Design is followed by PHP (programming), Photoshop, Website Design and HTML (programming). These are typically the best skills for any new freelancer to focus on initially when starting their freelancing journey. How Electronic Repairs Are Becoming the Fastest Growing Skill Globally Electronic Repairs has emerged as one of the fastest-growing job categories on the platform over the past year. In Q2 2024, it ranked 19th among the top 25 fastest-growing jobs, with a 10.7% increase (from 14,945 to 16,548 jobs). However, its most impressive growth is evident in the year-over-year comparison, where Electronic Repairs jobs surged by 162%, from 6,315 in Q2 2023 to 16,548 in Q2 2024. Electronic Repairs are in-person jobs where freelancers are deployed across select countries and cities to fix laptops, printers and computer hardware as part of the Freelancer Global Fleet Program. ##### Fast 50 The Fast 50 index is the world’s largest forward indicator of trends in online jobs related to industries, technologies, products, and companies. The data is based on 251,000 jobs posted to the platform between 1st April to 30th June 2024. Data: Fast 50 Quarterly Index – Q2 2024 2023 Q2 v 2024 Q2 Fastest Growing Jobs for Q2 2024 Fastest Falling Jobs for Q2 2024 About Freelancer Twelve-time Webby award-winning is the world’s largest freelancing and crowdsourcing marketplace by total number of users and projects posted. More than 74 million registered users have posted over 23.8 million projects and contests to date in over 2,000 areas as diverse as website development, logo design, marketing, copywriting, astrophysics, aerospace engineering and manufacturing. Freelancer owns and Loadshift. Freelancer Limited is listed on the Australian Securities Exchange under the ticker ASX:FLN and is quoted on OTCQX Best Market under the ticker FLNCF. Contact Details Marko Zitko +1 650-800-6863

July 18, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Ascend Wellness CEO Outlines Company's Growth Strategy and Market Expansion Plans

Ascend Wellness Holdings

Ascend Wellness CEO John Hartman joined Steve Darling from Proactive to discuss the company’s current status and future plans. Ascend Wellness, a prominent multi-state cannabis operator in the United States, has established its presence primarily in the Midwest, Northeast, and Mid-Atlantic regions. The company, now in its fifth year of operation, has expanded its footprint to seven states, including Ohio and Pennsylvania, both of which are transitioning to recreational cannabis use. During the interview, Hartman emphasized Ascend Wellness's strategic approach of focusing on select markets and maximizing the number of dispensaries allowed in each state. This targeted strategy is aimed at optimizing market penetration and ensuring robust growth. Drawing on his extensive background in wholesale, retail, and manufacturing, Hartman highlighted the company's emphasis on effective capital deployment and growth through mergers and acquisitions (M&A). A significant development discussed was the refinancing of a term loan due in August 2025. This financial maneuver provides Ascend Wellness with a five-year runway to concentrate on growth initiatives. The refinancing is expected to enhance the company's balance sheet management, providing greater financial stability and flexibility. Contact Details Proactive North America +1 604-688-8158

July 17, 2024 10:42 AM Eastern Daylight Time

Article thumbnail News Release

Briefly Bio launches with $1.2m funding to help scientists reproduce complex experiments

Briefly Bio

Science is in a reproducibility crisis. In preclinical research, it’s estimated that over 50% of efforts to reproduce experiments fail, costing the industry over $50bn each year. Solving this problem, techbio startup Briefly Bio has launched with software that makes lab work more reproducible by helping scientists capture and share their work clearly and consistently. With this launch, Briefly Bio has secured a $1.2m pre-seed funding round. It was led by Compound VC, with participation from NP Hard, Tiny VC and angel investors across tech and biotech. Biological experiments have become increasingly complex. With this growing complexity, details that are critical to our shared understanding are often undocumented and lost. This makes scientific collaboration inefficient: lab scientists struggle to reproduce and build on top of each other's experiments; data scientists do not have the necessary context to analyse the data produced in their labs; and automation teams lack all details to build robotic labs. Briefly Bio is tackling this, creating a shared language for experiments that is consistent across scientists, and clear for any collaborator to understand. Their software uses AI to convert existing experiment descriptions into this consistent format, while automatically filling in gaps and spotting errors. This helps capture the value of every experiment that is run, and enables scientists to learn from each other’s work. Briefly was founded by Dr Katya Putintseva, Harry Rickerby and Staffan Piledahl. They have varied backgrounds, through academia, tech, biotech and robotics. Before founding the company, the three worked together at drug discovery startup LabGenius, where they helped build its ML-driven antibody discovery platform. Harry Rickerby, CEO and co-founder at Briefly Bio, commented: “Scientific methods are a bit like software code, they are a set of instructions that define how an experiment should be run. The majority of this ‘code’ is incomplete, since writing up each experiment completely takes a huge amount of effort. Now, with LLMs, there’s a way to make these methods consistent without imposing on a scientists’ workflow. As Github helped software engineers collaborate and build on each other’s code, we think Briefly can help scientists and engineers do the same with their experiments.” With AI and high throughput experimentation, there is an opportunity for huge improvements in the efficiency of scientific discovery. Hundreds of billions of dollars are being invested through startups and big pharma to take advantage. To realise this potential, science needs more consistency and transparency in how these datasets are generated, since the value of any model is a product of the data it has been trained on. Briefly Bio is building this necessary layer of infrastructure to accelerate scientific discovery in biology. “This is a revolution in documenting lab experiments. It is the future of foolproof knowledge-sharing between scientists” said Dr Gena Nikitin, Founder of Miphic. While Dr Maria Anastasina, Wet Lab Head at the Evolutionary and Synthetic Biology Unit, OIST, added: “Briefly has become a core part of our lab's knowledge base and a great help to me in training researchers and lab management”. And Suparna Kumar, PhD student at Weill Cornell commented: “Briefly Bio has become an indispensable part of my lab routine because it helps me save so much time”. Rob Harkness, CTO of Biosero, added: “We're very excited by what Breifly.Bio can offer with their software tools. Inconsistent and incomplete data can compromise research, making it difficult to reproduce experiments and undermining trust in scientific results. Digitalising and automating laboratory operations can address this, but this effort faces challenges of inefficiency and high error rates, primarily due to the diverse formats in which workflows are presented. addresses this by converting scientific protocols written in natural language into a common and consistent structured format. This facilitates much faster design and implementation of automated systems, ensuring all critical information is captured and utilized effectively. The result is a significant boost in workflow integration, efficiency, and data quality, all of which are crucial for generating reliable experimental results. This leads to more comprehensive and innovative solutions in lab automation that can only help accelerate scientific research.” Shelby Newsad, Investor at Compound, commented: “The crux of successful science lies in consistent and executable methods. Whereas most bio software companies focus on data and its analysis, Briefly goes upstream to the core problem space of reproducibility via protocols. For the first time in science history, this incentivizes scientists to share more of their previously tacit knowledge. The fact that Briefly-made methods can be built and collaborated upon creates unique potential for network effects from their software.” Briefly Bio is creating a future where scientists can stop reinventing the wheel – spending time and resources on experiments that they can’t reproduce. This will enable scientists to produce datasets that will quickly expand our understanding of biology. About Briefly Bio Briefly Bio is the tool to make lab work reproducible. It helps scientists capture, share their experiments clearly and consistently. Briefly is based in London, UK. For more information, visit About Compound VC Compound is a research-centric, thesis-driven investment firm. We are a team of investors, researchers, and operators. We use our domain expertise, network, and prior experiences to help our founders solve previously unsolvable technical problems, communicate these breakthroughs to the world, and scale commercialization. Contact Details Briefly Bio Bilal Mahmood +44 7714 007257 Company Website

July 17, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

University Compounding Pharmacy Announces Rebrand to MediVera Compounding Pharmacy™


University Compounding Pharmacy, a leader in personalized medicine since 1999, today announced it is rebranding as MediVera Compounding Pharmacy™. The rebrand comes at a time when the company is growing strongly due to the introduction of new product offerings, nationwide expansion, and the successful differentiation of its quality products and services. Despite the name change, the company’s ownership and passionate team remain the same, ensuring continuity in the high-level service and exceptional care that healthcare providers and patients have relied on for more than two decades. Over the past few years, the company has seen its revenue grow substantially. New product offerings, nationwide expansion, and strong market positioning through differentiated quality products and services, such as the Impressed Advantage program, have enabled the company to double its revenue from 2022 to 2023. Growth is anticipated to accelerate this year, with the company expecting to double revenue year-over-year once again. “Differentiation is and will continue to be an important growth driver for our company. With the Impressed Advantage customer service program, we are making the prescription process easier, faster, and more convenient for both doctors and their patients,” said Bradley McCloskey, PharmD, CEO. “As we continue to launch more product offerings and expand into more states within the next few months, 2024 is poised to become a year of strong growth as we expand our footprint into 14 additional states.” For more information about MediVera Compounding Pharmacy and its services, please visit or contact Laurie Malseed, Marketing Specialist, at or 937-242-0430. About MediVera Since its inception in 1999, MediVera Compounding Pharmacy™ (formerly University Compounding Pharmacy) has been dedicated to providing personalized medicine. With a focus on quality and innovation, MediVera Compounding Pharmacy™ continues to set industry standards, offering tailored solutions to meet the unique needs of healthcare providers and patients. MediVera Compounding Pharmacy™ is currently licensed in and ships to the following 33 states: AZ, CN, CO, DE, FL, GA, IA, ID, IL, IN, KY, MA, MD, ME, MI, MN, MO, MT, NC, NH, NJ, NY, OH, PA, RI, SC, SD, TN, VA, VT, WA, WI, WY. Contact Details MediVera Compounding Pharmacy Laurie Malseed +1 937-242-0430

July 16, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Huma completes Series D with total financing of over $80m as it launches Huma Cloud Platform with GenAI integrations to bring digital first care and research to everyone


Building and launching a scalable digital health product that meets regulatory demands typically takes a few years to deliver. Today, global healthcare AI company Huma Therapeutics Limited is announcing the completion of its Series D funding round to help cut that time down to days as it launches the Huma Cloud Platform. The platform offers no-code configuration of regulated disease management tools for any therapeutic area, a library of pre-built modules and device connectivity capabilities, a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms, a marketplace, and more to advance digital-first care and research. The Series D funding round, alongside investments from leading industry partners since its Series C round, created a total issuance of shares by Huma of over $80m. With this round, Huma has now raised over $300m. The Series D saw the participation of new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer and others. HSBC Bank plc acted as advisor to Huma during the fundraise. Alongside its Series D, Huma is also announcing the launch of its Huma Cloud Platform – a technology ecosystem designed not only to support the company’s own digital health initiatives, but also to empower others to launch and scale their projects efficiently. With its Huma Cloud Platform and the regulatory foundation that it is built on, Huma aims to reduce the time it takes to develop and launch digital health projects at scale from years to as little as a few days. The Huma Cloud Platform is built to serve the company's existing regulated products. In 2023, Huma achieved the landmark milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EU MDR Class IIb, India CDSCO Class C and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. The regulatory status of the Huma Cloud Platform significantly reduces the cost, time, and risks associated with bringing digital health projects to life. Huma is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions. Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing commented: “We have known Huma for several years and we've been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.” “Pharmaceutical companies need financially and technically efficient digital solutions to minimise spending on efforts that are duplicative or can't scale. The Huma Cloud Platform enables companies to streamline how they bring digital medicine, companion apps, and data collection capabilities to patients from the R&D phase to post-launch.” To date, Huma’s technology has powered projects in over 3,000 hospitals and clinics. The platform has been used to engage and screen over 35 million individuals, with 1.8 million active users across its products in over 70 countries. Huma’s U.S. business has grown significantly since launch with new reimbursement codes. The RPM product, built on top of the Huma Cloud Platform for respiratory use cases, now covers 140,000 contracted lives. As a result of all these successes, the company has doubled its revenue year-on-year, and is targeting to become profitable this year. Huma also collaborates with over half of the top 20 pharmaceutical companies globally and has been involved in major national healthcare projects worldwide. Huma has partnered with Google and others to develop new AI models that could enable its Cloud Platform users to care for many times more patients with less work; for example a feature called “10x Nurse” that significantly reduces administrative tasks and brings automation to the patient review process with a human in the loop. This opens new possibilities, such as efficiently managing chronic diseases with fewer staff or using real-time monitoring systems to ensure patients are on the correct treatment pathways while keeping humans still in the loop. Looking ahead, combining the Huma Cloud Platform with next-generation AI models will enable Huma to have a bigger impact through its digital-first care and research initiatives, as well as supporting small startups and enterprises in launching the digital solutions they need. It promises to do this much faster and cheaper, shifting the focus to project or venture success rather than getting distracted with scaling technology or managing regulatory burdens. Dan Vahdat, Founder and CEO of Huma, said, “I am thankful for the support of our new and existing shareholders, helping our vision become a reality, which we are closer to than ever before. We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. This will help us transition medicine from being reactive to proactive.” About Huma Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Its award-winning modular platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users in healthcare, and has powered over 800 studies supporting about 1 million participants across research. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as collaborating with most large pharma companies. Huma's technology powers: ● multi-channel patient engagement at population-wide scale for healthcare systems ● remote patient monitoring (RPM) at scale ● companion apps to support patients through treatment and drug therapies ● digital clinical trials, including decentralised trials, to accelerate medical research Huma's regulated Software as a Medical Device, used in its RPM and companion app platforms, is the only disease- and device- agnostic platform to hold EU MDR Class IIb, US FDA (510-k) Class II clearance and Class IIb registration with the UK MHRA. The SaMD platform is regulated to accept artificial intelligence algorithms and monitor patients of all ages. For more information please visit Contact Details Huma Bilal Mahmood +44 7714 007257 Company Website

July 16, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Autonomix's Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Autonomix Medical (NASDAQ: AMIX) is a cutting-edge medical technology company developing targeted nerve therapies to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated. The company's ongoing proof-of-concept (PoC) human clinical trial is evaluating the safety and efficacy of radiofrequency (RF) ablation in a transvascular approach to reduce pain associated with pancreatic cancer and, to date, has demonstrated extremely compelling results. If successful, Autonomix has the potential to dramatically impact patient well-being and improve quality of life, offering new hope for patients enduring pancreatic cancer pain. Key Trial Insights The initial phase of the clinical trial involved five lead in patients who underwent the procedure without complications or significant adverse events. Some 60% of these subjects experienced a significant reduction in pain, with a mean decrease of 6.33 points on the Visual Analogue Scale (VAS) pain scale, dropping from a baseline of 8.0 to 1.67 just seven days post-procedure. Patients also reported quick pain relief, with some feeling better as soon as one day after the procedure​​. A detailed look at the data should provide Autonomix with important insight into optimizing the procedure, particularly the catheter entry point, where three of the five patients who benefited with meaningful pain reduction had femoral access to the catheter and the two that did not respond had brachial access. The primary objective of this PoC trial is to assess the success rate of ablating relevant nerves to mitigate pain in patients with pancreatic cancer using radiofrequency ablation. Secondary objectives include evaluating device- and procedure-related adverse events up to six weeks post-procedure, changes in pain levels and improvements in quality of life from pre- to post-procedure​​. Autonomix is proceeding with enrolling an additional 20 subjects to participate in the study and expects to complete enrollment by the end of 2024. The company expects to report topline results from all 20 subjects in the first half of next year. Clinical Trial Testimonials According to Autonomix, patients in the responder group reported substantial improvements in their quality of life. On average, these patients noted a 78% enhancement in how they viewed their overall health and a 45% boost in how they viewed their life quality, within seven days of the procedure. This rapid relief is crucial for individuals facing end-of-life situations due to advanced pancreatic cancer, offering them a better quality of life during their remaining time​​. Patient testimonial s further emphasize the impact of the procedure. Before the procedure, patients can struggle with debilitating pain, which affects their ability to sleep, eat and perform daily activities. Post-procedure, patients experienced immediate, life-changing pain relief and could sleep on their back, return to work and attend social events. Additionally, one patient stated they no longer needed painkillers, and experienced significant improvements in overall health and quality of life. This transformation underscores the procedure's potential to greatly enhance the lives of patients suffering from pancreatic cancer pain. Technical Approach And Future Plans Autonomix's technology aims to improve upon current pain management methods, which often rely on systemic drugs like opioids or invasive procedures that can have severe side effects. Autonomix’s catheter-based system is also designed to detect and ablate pain-associated neural signals more accurately. While the current trial focuses on pancreatic cancer-related pain, Autonomix also plans to explore other indications in the future based on these promising results. A New Dawn In Pain Management Autonomix’s innovative approach to pain management for pancreatic cancer patients is showing encouraging potential. The initial success of its PoC clinical trial offers a glimpse into a possible future where patients suffering from severe pain can find relief through precise and effective medical technology. As the company gathers more data, the medical community awaits its results, which could revolutionize pain management far beyond just pancreatic cancer pain and have applications across all pain and diseases of the peripheral nervous system. Featured photo by Alexander Grey on Unsplash Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC Company Website

July 12, 2024 08:45 AM Eastern Daylight Time

Article thumbnail News Release

Prenetics Global (NASDAQ: PRE): Bending Biotech with Beckham

RazorPitch - PRE

As the global population ages and the prevalence of chronic diseases rises, there is an increasing demand for innovative solutions that can enhance prevention, diagnosis, and treatment. The health sciences industry is undergoing a significant transformation, thanks to advances in genomics, personalized medicine, and early detection technology. One major example is the global cancer diagnostics market, which was valued at USD 19.5 billion in 2023 and is expected to reach USD 54.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.1% during the forecast period. In this dynamic landscape, one company has been making waves recently: Prenetics Global Limited (NASDAQ: PRE). PRE: A Key Player in Health Innovation Prenetics Global Limited (NASDAQ: PRE), a genomics-driven health sciences company, is making significant strides in the sector. The company operates through three primary units: CircleDNA, Insighta, and ACT Genomics, each contributing significantly to its mission of improving lives through science. CircleDNA: Offers one of the most comprehensive consumer DNA tests available, utilizing whole exome sequencing. This test provides extensive insights into an individual's genetic predispositions, promoting proactive health measures and personalized wellness plans. Insighta: A $200 million joint venture with renowned scientist Professor Dennis Lo, focuses on developing multi-cancer early detection technologies. The goal is to create a simple blood test that can detect multiple types of cancer at early stages, making early detection more accessible and affordable globally. ACT Genomics: The first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors through its ACTOnco test. This milestone enables personalized cancer treatments based on detailed genetic profiles, significantly enhancing treatment efficacy. Financial Performance and Strategic Milestones Prenetics Global has demonstrated robust financial performance. On June 19, 2024, the company announced its unaudited financial results for the first quarter ending March 31, 2024. The company reported revenue from continuing operations of $6.4 million, a notable 30.2% increase compared to the first quarter of 2023. Gross profit from continuing operations surged to $3.8 million, reflecting a 159.8% increase from the previous year. Adjusted EBITDA from continuing operations improved by 55.9%, resulting in a loss of $4.1 million. Additionally, the company maintained a robust cash position with $86.6 million in cash and other short-term assets as of March 31, 2024. Insighta held a cash balance of $79.8 million on the same date. Danny Yeung, Chief Executive Officer and Co-Founder of PRE, remarked, "The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit. These results demonstrate firm governance of our financial position with no debt, supported by a resilient and talented team." Strategic Focus on the US Market Prenetics Global is shifting towards the US consumer healthcare market to expand access to their health solutions. This move includes establishing dual headquarters to capitalize on new opportunities both domestically and globally. Yeung emphasized, "As we enter the second half of 2024, we are making significant strides in our strategic realignment with a keen focus on the consumer healthcare market in the USA. Our purpose remains dedicated to our science-first approach in our pivot to consumer healthcare to broaden accessibility to science-based health and wellness." Recent Appointments and Board Changes On July 1, 2024, PRE announced the addition of Kathryn M. Henry and David Vanderveen as independent directors to the company's Board of Directors. CEO Danny Yeung noted, "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." Partnership with David Beckham On July 11, 2024, Prenetics Global announced a new partnership with former international footballer, entrepreneur, and philanthropist David Beckham. Beckham has become a strategic investor in the business, and together with PRE, they will co-found a new health and wellness brand, IM8. Beckham expressed his excitement about the partnership, saying, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That’s why I am excited to be working with PRE - a company that is dedicated to innovative, world-leading scientific advancements in health - as a co-founding partner and ambassador for IM8.” Danny Yeung highlighted the significance of this collaboration, stating, "This partnership with David marks a transformative era for PRE in global health innovation and wellness. David epitomizes the values of discipline, teamwork, and health, aligning perfectly with PRE's core principles. Working closely with David these past months, I've been consistently inspired by his vision for accessible health for all. His passion and commitment are truly extraordinary. With IM8, we have a unique opportunity to contribute meaningfully to the consumer health and wellness industry." Conclusion Prenetics Global Limited (NASDAQ: PRE) is making significant progress in the genomics and health sciences sectors, with a strong focus on cancer prevention, detection, and treatment. The company's recent financial performance, strategic focus on the US market, promising clinical trials, and high-profile partnership with David Beckham highlight its potential for continued growth and innovation. Investors interested in genomics and health sciences may want to keep a close eye on PRE. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of content related to PRE. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details Mark McKelvie +1 585-301-7700 Company Website

July 12, 2024 06:00 AM Eastern Daylight Time

12345 ... 195